YTE Partners with Incyte to Expand Oncology Treatment Access in Asia-Pacific
- Specialised Therapeutics and Incyte expand partnership to introduce axatilimab and retifanlimab in Australia, New Zealand, and Singapore.
- ST will manage regulatory submissions and distribution, while Incyte handles development and manufacturing of the therapies.
- The collaboration aims to improve patient access to innovative oncology treatments in the Asia-Pacific region by 2025.
Strategic Collaboration Enhances Oncology Treatment Access in Asia-Pacific
Specialised Therapeutics (ST), an independent biopharmaceutical company, announces a significant expansion of its partnership with Incyte Biosciences International Sàrl to introduce two new oncology therapies: axatilimab (Niktimvo®) and retifanlimab (Zynyz®) in Australia, New Zealand, and Singapore. Building on their successful collaboration that began in 2021, which already includes the commercialization of Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib), this expanded agreement is poised to improve treatment options for patients with rare and difficult-to-treat conditions. By focusing on innovative therapies, both companies aim to address pressing unmet medical needs in the region.
Under the terms of the newly expanded agreement, Incyte will take charge of the development, manufacturing, and supply of axatilimab and retifanlimab, while ST will oversee regulatory submissions, distribution, and local marketing efforts. This delineation of responsibilities plays to the strengths of both organizations, allowing for a streamlined approach to bringing these important therapies to market. Carlo Montagner, CEO of ST, emphasizes the significance of this agreement, highlighting the company’s commitment to ensuring that patients affected by challenging medical conditions have access to advanced treatment options. The collaborative effort aims to submit both therapies for local regulatory and reimbursement approval by 2025, signaling a proactive approach to patient access.
Incyte’s CEO, Hervé Hoppenot, underscores the successful navigation of complex regional regulatory frameworks by ST and expresses optimism about the continued partnership. The synergy between the two companies reflects a shared vision of improving patient outcomes in the oncology space. With an expanding portfolio of innovative therapies, the collaboration stands to play a pivotal role in enhancing healthcare solutions across the Asia-Pacific region, ultimately ensuring that patients benefit from cutting-edge treatments.
In addition to the introduction of axatilimab and retifanlimab, the partnership signifies a broader commitment to addressing oncology challenges in the Asia-Pacific market. The ongoing collaboration not only strengthens the supply chain for these therapies but also reinforces the companies’ dedication to patient-centric care.
As the biopharmaceutical landscape evolves, the combined expertise of ST and Incyte positions them to meet the growing demand for effective oncology treatments, fostering a healthier future for patients in the region.
